Chimerix Inc

Chimerix — Investor Presentation (January 2017)

29 slides from Chimerix's investor presentation, Jan 6, 2017

  1. Slide 1: Corporate Overview January 2017

    DEDICATED TO PREVENTING AND TREATING LIFE - THREATENING VIRAL INFECTIONS Corporate Overview January 2017

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements These slides and the accompanying oral presentation contain forward - looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility tha

  3. Slide 3: Brincidofovir (BCV, CMX001)

    3 Brincidofovir (BCV, CMX001) 1. Papanicolaou G, et al. European Society for Blood and Marrow Transplantation (EBMT), April 2014. 2. Morrison M, et al. World Transplant Congress, July 2014. ▪ Broad - spectrum antiviral with high in vitro potency against all herpes viruses, adenovirus subtypes, other

  4. Slide 4: BCV: Only Broad Spectrum Antiviral in Development

    4 BCV: Only Broad Spectrum Antiviral in Development Vi r a l F am ily Virus BCV Ci do f o vir M a ri b a vir Let e rm o vir G a n c i c l o vir* F o s c a r ne t A c y c l o vir H e rp e s C y t om e g a lovirus 0 . 00 1 0 . 4 0 . 31 0 . 005 3 . 8 5 0 - 800 > 2 00 E p s t e i n - B a rr Virus 0 . 0

  5. Slide 5: Stem Cell Transplant Recipients are at High Risk of Viral Disease and Mortality

    Stem Cell Transplant (HCT) Recipients are at High Risk of Viral Disease and Mortality ▪ Allogenic stem cell transplant (HCT) recipients face 20% mortality in the first year after transplant ▪ DNA viruses commonly reactivate in these patients as early as the first week after transplant Risks for high

  6. Slide 6: BCV Market Opportunities: Global Opportunities in Transplant and Malignancies

    6 BCV Market Opportunities: Global Opportunities in Transplant and Malignancies TRANSPLANTS PER YEAR US European ROW TOTAL Union (28) HCT Allogeneic 8,500 16,400 8,500 33,400 Autologous 14,000 21,700 12,000 47,700 HCT TOTALS 22,500 38,100 20,500 81,100 SOT Kidney 18,600 20,000 40,700 79,300 Liver 7,

  7. Slide 7: SUPPRESS for CMV Prevention: Brincidofovir Efficacy Was Confounded by GI Toxicity

    7 SUPPRESS for CMV Prevention: Brincidofovir Efficacy Was Confounded by GI Toxicity ▪ Statistically - significant reduction in CMV reactivation in high - risk allo - HCT while on therapy ▪ Higher rate of misdiagnosis of gut GVHD due to drug - related diarrhea in subjects randomized to BCV ▪ Gut biop

  8. Slide 8: Intravenous Brincidofovir

    INTRAVENOUS BRINCIDOFOVIR —

  9. Slide 9: Preclinical Data Provide Confidence that IV BCV Will Address Oral BCV's GI Toxicity

    Preclinical Data Provide Confidence that IV BCV Will Address Oral BCV’s GI Toxicity 28 - day rat studies of IV BCV: ▪ No animals had diarrhea ▪ All animals gained expected weight during study ▪ No GI findings in intestines at terminal necropsy ▪ No in - life clinical findings at highest dose: IV BCV

  10. Slide 10: IV BCV Delivers Uniform Drug Exposure to Key Organs

    IV BCV Delivers Uniform Drug Exposure to Key Organs 0 2000 4000 6000 8000 10000 12000 Liver Kidney Cortex Kidney Medulla Small Intestine AUC all ( µg - equiv*h/g) Total Drug Exposure (AUC all ) in Clearance Organs (rats) IV PO 10 ▪ IV BCV prevents “over - exposure” of gut , with significant improvem

  11. Slide 11: IV BCV Single Ascending Dose Study in Healthy Subjects: No GI Toxicity

    11 IV BCV Single Ascending Dose Study in Healthy Subjects: No GI Toxicity ▪ IV BCV 10 mg and 25 mg cohorts are complete ▪ IV BCV 10 mg provides similar exposure as oral BCV 100 mg ▪ Both IV BCV doses were generally safe and well - tolerated: – no drug - related AEs – no gastrointestinal AEs – no gra

  12. Slide 12: IV BCV Avoids GI Side Effects, Provides Opportunities for All DNA Viruses

    12 IV BCV Avoids GI Side Effects, Provides Opportunities for Treatment of All DNA Viruses Oral BCV IV BCV Broad Spectrum ✔ ✔ NO heme toxicity ✔ ✔ NO kidney toxicity ✔ ✔ Prevention of CMV in HCT ✔ Treatment of CMV ✔ Prevention of AdV in HCT ✔ Treatment of AdV ✔ ✔ Treatment of smallpox ✔ ✔ Treatment o

  13. Slide 13: IV BCV Delivers More Drug to Difficult-to-reach Compartments Including the Brain

    IV BCV Delivers More Drug to Difficult - to - reach Compartments Including the Brain 0 2 4 6 8 10 12 14 Brain, Cerebellum Brain, Cerebrum and Medulla Spinal Cord AUC all (ug equiv*h/g) Total Drug Exposure (AUC all ) in CNS Tissues (rats) IV PO 13 ▪ Higher CNS exposures with IV BCV could support test

  14. Slide 14: IV BCV Summary, Next Steps for IV and Oral BCV

    IV BCV Summary, Next Steps for IV and Oral BCV IV BCV ▪ Single Ascending Dose Study in healthy subjects continues, with two additional cohorts scheduled ▪ Multiple - ascending dose study in healthy subjects to initiate in 1H 2017 ▪ Phase 2 dose - ranging studies in CMV and BKV infections to follow ▪

  15. Slide 15: Smallpox: Oral Brincidofovir for Treatment of Smallpox

    SMALLPOX ORAL BRINCIDOFOVIR FOR TREATMENT OF SMALLPOX

  16. Slide 16: Oral BCV for Smallpox

    16 Oral BCV for Smallpox ▪ Efficacy to be demonstrated via two animal model studies under FDA’s Animal Rule – Pivotal Rabbitpox Efficacy Study demonstrated 100% survival in animals treated immediately with BCV at the time of confirmed infection – Mouse ( ectromelia ) efficacy study results expected

  17. Slide 17: Adenovirus: Oral Brincidofovir for Treatment of Adenovirus

    ADENOVIRUS ORAL BRINCIDOFOVIR FOR TREATMENT OF ADENOVIRUS

  18. Slide 18: Adenovirus Rapid Virologic Response on Oral BCV Correlated with Improved Survival

    First Quartile (n=15) Fourth Quartile (n=14) >2 doses cidofovir 11 (73%) 2 (14%) Days from AdV diagnosis (median, IQR in days) 22 (12, 44 ) 6.5 (4, 9) AdV VL (median, IQR in log 10 c/mL) 5.4 (3.1, 6.1) 3.6 (2.3, 5.8) Mortality @ Wk 24 67% (10 of 15) 14% (2 of 14) 18 Adenovirus Rapid Virologic Respon

  19. Slide 19: AdVise Case Study: BCV Delivered Robust Antiviral Response, Patient Survived

    19 AdVise Case Study: BCV Delivered Robust Antiviral Response, Patient Cleared Infection & Survived 2 year - old cord blood transplant recipient with life - threatening AdV infection AdV Viral Load rises on off - label IV cidofovir After brincidofovir begun: Rapid decline in AdV in blood, urine and

  20. Slide 20: Oral BCV for Treatment of AdV in Pediatric HCT: Study

    20 Oral BCV for Treatment of AdV in Pediatric HCT: Study 999 Confidential ▪ Small (n~100), open label, comparative study of BCV vs. standard of care ▪ Inclusion: pediatric HCT recipients with > 1000 c/mL AdV DNA in plasma ▪ Primary endpoint: proportion with undetectable plasma AdV at Week 4 – N=100

  21. Slide 21: Demand for Brincidofovir Remains Strong

    21 Demand for Brincidofovir Remains Strong More than 900 patients with AdV have received brincidofovir since 2009 through Development and Expanded Access Programs Pediatrics Adults TOTAL Asymptomatic Symptomatic a Asymptomatic Symptomatic a All EINDs/NPP - 308 - 225 540 b Study 202 24 3 10 2 39 c St

  22. Slide 22: BCV: An Opportunity For Treatment of AdV Infection

    22 BCV: An Opportunity For Treatment of AdV Infection in 6000+ Hospitalizations Annually US AdV - Related Hospitalizations: 2009 - 2013 Actual, Trended From 2014 ▪ In addition to stem cell and organ transplant recipients, other at - risk populations include newborns with severe combined immunodefici

  23. Slide 23: Oral BCV for AdV: Potential First EU Indication

    23 Oral BCV for AdV: Potential First EU Indication In stem cell transplant recipients, AdV viral load is often very high and is strongly associated with fatal outcomes 1,2 Currently no approved therapy; significant limitations with current off - label use of cidofovir and decreasing immunosuppressio

  24. Slide 24: Norovirus: CMX521 for Norovirus

    NOROVIRUS CMX521 FOR NOROVIRUS

  25. Slide 25: Norovirus: Treatment and Prevention of Infections Presents a Significant Opportunity

    Norovirus: Treatment and Prevention of Infections Presents a Significant Opportunity ▪ Noroviruses is the most common cause of epidemic acute gastroenteritis worldwide ▪ $60B each year in healthcare utilization and lost productivity ▪ >60% of norovirus outbreaks in the US are in healthcare facilitie

  26. Slide 26: Candidate for Norovirus: CMX521

    26 Candidate for Norovirus: CMX521 ▪ Norovirus: RNA viruses, previously referred to as Norwalk ▪ CMX521: nucleoside that targets virus RNA polymerase, enabling broad activity against diverse (likely all) wild - type strains ▪ High barrier to resistance in vitro, with >50 passages required to confer

  27. Slide 27: Chimerix Pipeline

    Chimerix Pipeline Program Discovery Pre - clinical Phase 1 Phase 2 Phase 3 Anticipated Approval Oral BCV AdV Pediatric Treatment 2020 Smallpox IV BCV Multiviral Prevention BKV Treatment CMV Treatment CMX521 Norovirus CMX157 HBV Treatment Business Development Data from second animal study in 2017 † D

  28. Slide 28: Chimerix: 2017 Potential Catalysts

    28 Chimerix: 2017 Potential Catalysts 1H 2017 • Oral BCV: Complete second animal model efficacy for smallpox infection to complete requirements under FDA’s Animal Rule • IV BCV: Present final IV BCV clinical data from single ascending dose study, initiate multiple dose study • CMX521 for Norovirus:

  29. Slide 29: Our Mission Reflects Our Dedication to Patients

    29 Our Mission Reflects Our Dedication to Patients Dedicated to discovering and developing medicines to improve outcomes for immunocompromised patients Advance brincidofovir for the prevention and treatment of DNA virus infections in hematopoietic cell transplant (HCT) and solid organ transplant (SO

Chimerix — Investor Presentation (January 2017) on 6ix